Cassidy backs Schwartz for CDC director
Analysis based on 7 articles · First reported Jul 23, 2026 · Last updated Jul 24, 2026
The nomination of a CDC director with vaccine-skeptic ties could affect public health confidence and pharmaceutical company reputations. However, Cassidy's support suggests a smoother confirmation process, reducing near-term uncertainty for healthcare stocks.
Senator Bill Cassidy, chairman of the Senate Health, Education, Labor, and Pensions Committee, announced on July 23, 2026, that he would support the nomination of Dr. Erica Schwartz to lead the United States — Centers for Disease Control and Prevention (CDC). This marks a shift from his earlier skepticism during Schwartz's confirmation hearing, where he pressed her on whether she would stand up to Health and Human Services Secretary Robert F. Kennedy Jr. on vaccine policy. Cassidy cited further conversations with Schwartz and a modification to the HHS website regarding vaccines and autism as signs of good faith. The committee postponed the vote on Schwartz's nomination until the following week due to attendance issues. If confirmed, Schwartz would inherit an agency facing a measles resurgence, an Ebola outbreak in the Democratic Republic of Congo and Uganda, and a major foodborne illness outbreak. The committee also removed Sean Kaufman's nomination for assistant health secretary from the schedule.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard